title: Lung cancer genetics and pharmacogenomics.
abstract: Epidermal growth factor receptor (EGFR)-targeted therapies have demonstrated remarkable success in a small subset of non-small cell lung cancer patients. The mechanism of response has been an area of active research, with somatic mutation in a number of genes in the EGFR signal transduction pathway and copy number alterations of genes of the EGFR family as candidates contributing towards response. Continuing studies should help determine an appropriate biomarker or combination of biomarkers that can be used to predict response to this class of therapy.
authors.affiliation: Harvard Medical School-Partners, Healthcare Center for Genetics and Genomics, Cambridge, MA, USA. vjoshi@partners.org
authors.forename: V A
authors.initials: VA
authors.lastname: Joshi
authors.forename: R
authors.initials: R
authors.lastname: Kucherlapati
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D014408:Biomarkers, Tumor; D066246:ErbB Receptors / Q000235:genetics*; D005091:Exons; D018628:Gene Dosage; D015972:Gene Expression Regulation, Neoplastic; D005838:Genotype; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D009154:Mutation; D020411:Oligonucleotide Array Sequence Analysis; D010597:Pharmacogenetics / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D066246:ErbB Receptors